Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial

RCT (n=596) reported day 11 clinical status distribution was significantly better for 5-day course of remdesivir vs standard care (OR, 1.65; 95% CI, 1.09-2.48; P = 0.02) but not for 10-day course vs standard care (P = 0.18). The clinical importance of these findings are uncertain

SPS commentary:

A related editorial discusses these findings in the context of other clinical trials of remdesivir and notes the uncertainty regarding the efficacy of remdesivir, “First, the optimal patient population is unclear. Second, the optimal duration of therapy is unclear. Third, the effect on discrete clinical outcomes is unclear. Fourth, the relative effect of the drug if given in the presence of dexamethasone or other corticosteroids is unclear.”


Journal of the American Medical Association

Resource links: